ABBISKO-B (02256) successfully commercialized the core drug Beijiemai in the first half of the year, with continued ramp-up of R&D investment.

ABBISKO-B (02256) announced its mid-year performance for 2026, with revenue approximately 97.265 million yuan, gross profit of 95.505 million yuan, and research and development expenses of about 246 million yuan, representing an 8% year-on-year growth. The announcement stated that revenue mainly comes from milestone and sales share income related to the commercialization of Beijiemai from Merck. The increase in R&D expenses is primarily due to the advancement of pipeline projects. Since the beginning of 2026, the company has made significant progress in many areas. Through its strategic partnership with Merck KGaA, Darmstadt, Germany, the company successfully achieved a major milestone by commercializing its core pipeline candidate drug Beijiemai (ABSK021) in China. At the same time, the company continues to advance multiple clinical projects, including registration studies, combination therapy strategies, and the expansion of its early-stage R&D pipeline. Additionally, through strategic collaborations with Eli Lilly and Company and AstraZeneca, the company has further strengthened its global partner network. These collaborations fully demonstrate the company's strengths in drug R&D and clinical development and provide strong support for its goal of creating long-term value based on its innovative pipeline and platform.